Accelerating Breakthrough Discoveries into Medicines

Ferozrpapa from OptiKira talking in a lab

Scientists in lab examining solution

From research institutions to patients

BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Led by experienced industry professionals

BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.

Pharmaceutical Expertise

Our leadership and portfolio teams are well-versed in translational science, with deep pharmaceutical experience having supported the advancement of numerous programs into clinical development and into the marketplace.

Deep Business Networks

Through their careers, the company’s leadership team and advisory board members have developed broad relationships in the investment and pharmaceutical industries that are available to be accessed by BioMotiv companies.

Partnered with leading companies

Working with
The Harrington Project
to bridge the Valley of Death


News

SapVax Launched to Develop Novel Cancer Vaccines Platform

CLEVELAND, OH – January 17, 2017 SapVax will develop a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology for immuno-oncology applications.  It was formed by BioMotiv and UniServices, the commercialization...

Harrington Discovery Institute Announces 15 New Scholars

CLEVELAND, OH – January 16, 2017 The Harrington Discovery Institute (HDI) at University Hospitals in Cleveland, Ohio has announced 15 new recipients of the Harrington Scholar-Innovator and Partnership Awards. The Partnership Scholars were selected in...